|
|
|
|||
|
|
|
|
|
|
Calcium Reduces Long Term Colon Polyp Cancer Risk Taking calcium supplements protects against
the development of colon polyps, which can become cancerous, and this
benefit appears to persist for up to 5 years after people stop taking the
supplements, according to a new study. In 1999, data from the Calcium Polyp Prevention Study involving 930 adults, who were randomly assigned to take an inactive placebo or 1200 milligrams calcium daily for 4 years, showed a 20 percent reduction in the risk of all colorectal cancers with calcium supplementation. At the meeting, Baron reported data on 822 of the original participants who were followed for at least 5 years after the end of the treatment phase of the study. During that period, there was a 41 percent reduction in the risk of polyps and a 35 percent reduction in risk of all colon cancers. "These were more pronounced reductions than were seen during the treatment phase," Baron said. This reduction in risk did not persist beyond 5 years after the calcium supplements were stopped. These data, Baron said, indicate that
"calcium is effective in reducing the risk of colorectal adenomas and,
after the end of the supplementation, there is no rebound in risk at all.
In fact there appears to be a delayed, more pronounced suppression of
colorectal neoplasia during the 5 years after treatment." Calcium May Help Prevent Colorectal Cancer Calcium, whether
taken as a supplement or in your diet, can help prevent colon cancer. The researchers didn't only want to see if
calcium affected colon cancer. They also were curious about whether the
source of calcium made a difference. Were calcium-rich foods or
supplements more helpful? To find out, the women were grouped by their
calcium intake from food and supplements.
High-Glycemic Diet Raises Colorectal Cancer Risk Higher Selenium Levels Linked to Lower Colorectal Cancer Risk The Journal of the National Cancer Institute published an analysis of data derived from three randomized trials, which revealed that an elevation of blood selenium confers protection against the recurrence of colorectal adenomas, which are precursors of colorectal cancer. The findings were reported in the November 17 2004 issue of the journal. The current study analyzed three trials that examined the ability of nutritional therapies to prevent colorectal adenoma recurrence: the Wheat Bran Fiber Trail, the Polyp Prevention Trial and the Polyp Prevention Study. Serum selenium levels were ascertained from blood samples provided by 1,763 participants upon enrollment. The reoccurrence of adenomas were ascertained by colonoscopies conducted during the studies' follow up periods. In all trials, participants whose selenium levels were the highest experienced the lowest risk of developing a new colorectal adenoma. It was discovered that subjects whose blood selenium was in the top one-fourth of participants had a 34 percent lower risk of a new adenoma than those whose selenium was in the lowest quarter. In an accompanying editorial (96, 22:1645-7, 2004) entitled, “Can selenium prevent colorectal cancer? A signpost from epidemiology,” Scott M Lippman, MD and and Imad Shureiqi of the University of Texas M.D. Anderson Cancer Center, and Anna J Duffield-Lillico of Memorial Sloan-Kettering Cancer Center observe that oxidative metabolism of arachidonic and linoleic acids contribute to the formation of colon tumors. Selenium and selenium-containing compounds, are well known for their antioxidant activity. There is also evidence that the inhibition of cell growth observed in selenium-treated cultured cells is accomplished in part by a reduction in mechanisms dependent upon cyclooxygenase 2 (COX-2). Dr Lippman and colleagues predict that the findings of this analysis should intensity the interest in clinical trials of selenium and/or other compounds in the prevention of colorectal adenomas. SOURCE: Jacobs ET, Jiang R, Alberts DS, Greenberg ER, Gunter EW, Karagas MR, Lanza E, Ratnasinghe L, Reid ME, Schatzkin A, Smith-Warner SA, Wallace K, Martinez ME. Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst. 2004 Nov 17;96(22):1669-75. Soybeans
May Help Block Colon Cancer A substance found in
soybeans may reduce the risk of colon cancer, the world's third most
common form of cancer. Georgia Tech
researcher Dr. Al Merrill, along with colleagues from Emory University and
the Karmanos Cancer Institute, found that soy glucosylceramide, or soy
GlcCer, was effective in reducing the formation and growth of tumor cells
in the gastrointestinal tract in mice. The results are
published in the May 2004 issue of the Journal of Nutrition. Soy GlcCer is just
one of the many types of sphingolipids found in plants and animals.
Merrill and colleagues have already shown that milk sphingolipids can
suppress tumor formation. But this is the first study to deal with colon
cancer, he said. Reduction of Side Affects of Anticancer Drugs (6-mercaptopurine) by AHCC Active Hexose Correlated Compound (AHCC), mycelia extracts of cultured basidiomycetes, was examined in animal models to relieve side effects, such as anemia, alopecia and liver injury induced by anticancer drugs. 1. Male ddY mice were treated with fluorouracil (5-FU, 50 mg/kg) or cyclophosphamide (CY, 100 mg/kg) or both daily for 14 days by l.p. and AHCC was given in a 5% diet for the same period. Treatment with 5-FU or/and CY resulted in body weight loss, decrease in the numbers of peripheral cells in blood and polychromatic erythrocytes in bone marrow and were significantly restored by coadministration with AHCC. 2. Male and female SD rats received cytosine arabinoside (Ara-C, Lp., 50 mg/kg. daily) for 7 days. AHCC was given for the same period by either p.o. (500 mg/kg). Lp. (500 mg/kg) or local swabbing 10% AHCC-solution). The rats treated with Ara-C showed severe alopecia (50-100% hair loss). However, coadministration of Ara-C with AHCC protected from alopecia, especially when AHCC was given p.o. in which only slight alopecia (0-50% hair loss) was observed. 3. Male ddY mice were treated with mercaptopurine (6-MP, 30 mg/kg) and metholrexate (MTX. 2.5 mg/kg) by p.o. for 4 weeks. AHCC was given at a dose of 1 g/kg simultaneously. Treatment with 6-MP and MTX resulted in the decreases of body weight gain, serum albumin and triglyceride levels, liver drug-metabolism enzyme activities and the increases of liver weights. sGPT and sGOT levels obviously. The liver injury was significantly improved by the coadministratlon with AHCC. The results show that AHCC relieved the side effects induced by anticancer drugs in animals. Reference: Sun. B., Mukoda, T., Kosuna, K., and Okada, F. Proceedings of the American Association for Cancer Research. Volume 40 March 1999 |
|
||||||||||||||||||||||
5-HTP -
7-Keto DHEA -
Acai
- Acetyl
L-Carnitine -
Ageless Face, Ageless Mind -
AHCC -
Albizzia -
Alpha-Lipoic Acid and
R-Lipoic
Acid -
Age-Related Macular
Degeneration -
Air
Pollution -
Home
|
Specials | Product Info |
Old Health News | FAQs |
About us |
Blog |
Links |
Links2 |
Links3 | Sitemap |
Contact us
Alphabetic Product Listing |
Products
by Category |
Links4 |
Links5
TOLL FREE: 800-401-9186
Terms of Use | Privacy Policy | Terms and Conditions of Sale | Disclaimer
Copyright © 2001-2008, Discount Herbs & Vitamins, Inc. All rights reserved.
These statements have not
been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.
Please consult a qualified medical practitioner for medical advice.